These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 22563239)

  • 81. When to initiate and discontinue biologic treatments for rheumatoid arthritis?
    Chatzidionysiou K; van Vollenhoven RF
    J Intern Med; 2011 Jun; 269(6):614-25. PubMed ID: 21261760
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Tocilizumab: a review of its safety and efficacy in rheumatoid arthritis.
    Jones G; Ding C
    Clin Med Insights Arthritis Musculoskelet Disord; 2010 Dec; 3():81-9. PubMed ID: 21234291
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions.
    Nishimoto N; Ito K; Takagi N
    Mod Rheumatol; 2010 Jun; 20(3):222-32. PubMed ID: 20221663
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Patient preferences in the choice of anti-TNF therapies in rheumatoid arthritis. Results from a questionnaire survey (RIVIERA study).
    Scarpato S; Antivalle M; Favalli EG; Nacci F; Frigelli S; Bartoli F; Bazzichi L; Minisola G; Matucci Cerinic M;
    Rheumatology (Oxford); 2010 Feb; 49(2):289-94. PubMed ID: 19920093
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study.
    Jones G; Sebba A; Gu J; Lowenstein MB; Calvo A; Gomez-Reino JJ; Siri DA; Tomsic M; Alecock E; Woodworth T; Genovese MC
    Ann Rheum Dis; 2010 Jan; 69(1):88-96. PubMed ID: 19297346
    [TBL] [Abstract][Full Text] [Related]  

  • 86. An audit of hospital based outpatient infusions and a pilot program of community-based monoclonal antibody infusions.
    Doran JP; Alraqi S; Callanan I; FitzGerald O; Bresnihan B; Veale DJ
    Ir J Med Sci; 2009 Dec; 178(4):497-501. PubMed ID: 19129975
    [TBL] [Abstract][Full Text] [Related]  

  • 87. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.
    Saag KG; Teng GG; Patkar NM; Anuntiyo J; Finney C; Curtis JR; Paulus HE; Mudano A; Pisu M; Elkins-Melton M; Outman R; Allison JJ; Suarez Almazor M; Bridges SL; Chatham WW; Hochberg M; MacLean C; Mikuls T; Moreland LW; O'Dell J; Turkiewicz AM; Furst DE;
    Arthritis Rheum; 2008 Jun; 59(6):762-84. PubMed ID: 18512708
    [No Abstract]   [Full Text] [Related]  

  • 88. Response rates and responsiveness for surveys, standards, and the Journal.
    Fincham JE
    Am J Pharm Educ; 2008 Apr; 72(2):43. PubMed ID: 18483608
    [No Abstract]   [Full Text] [Related]  

  • 89. Treatment choices, preferences and decision-making by patients with rheumatoid arthritis.
    Chilton F; Collett RA
    Musculoskeletal Care; 2008 Mar; 6(1):1-14. PubMed ID: 17726671
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Safety and patient satisfaction of infliximab administration in an extramural setting supervised by a rheumatology specialist nurse.
    van Eijk Y; Boonen A; Schulpen G; Schrijnemaekers V; Fiolet H; van der Linden S
    Ann Rheum Dis; 2006 Feb; 65(2):276. PubMed ID: 16410538
    [No Abstract]   [Full Text] [Related]  

  • 91. Validation of single-factor structure and scoring protocol for the Health Assessment Questionnaire-Disability Index.
    Cole JC; Motivala SJ; Khanna D; Lee JY; Paulus HE; Irwin MR
    Arthritis Rheum; 2005 Aug; 53(4):536-42. PubMed ID: 16082630
    [TBL] [Abstract][Full Text] [Related]  

  • 92. The Stanford Health Assessment Questionnaire: dimensions and practical applications.
    Bruce B; Fries JF
    Health Qual Life Outcomes; 2003 Jun; 1():20. PubMed ID: 12831398
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Measurement of patient outcome in arthritis.
    Fries JF; Spitz P; Kraines RG; Holman HR
    Arthritis Rheum; 1980 Feb; 23(2):137-45. PubMed ID: 7362664
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Survey of a community-based infusion program for Australian patients with rheumatoid arthritis requiring treatment with tocilizumab: patient characteristics and drivers of patient satisfaction and patient-perceived benefits and concerns.
    Voight L
    Patient Prefer Adherence; 2012; 6():275-83. PubMed ID: 22563239
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Tocilizumab: a review of its use in the management of rheumatoid arthritis.
    Oldfield V; Dhillon S; Plosker GL
    Drugs; 2009; 69(5):609-32. PubMed ID: 19368420
    [TBL] [Abstract][Full Text] [Related]  

  • 96. The impact of tocilizumab on physical function and quality of life in patients with rheumatoid arthritis: a systematic literature review and interpretation.
    Townes SV; Furst DE; Thenkondar A
    Open Access Rheumatol; 2012; 4():87-92. PubMed ID: 27790016
    [TBL] [Abstract][Full Text] [Related]  

  • 97.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 98.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 5.